ArticleInternational journal of cardiology. Heart & vasculature2025
Clinical utility of segmental native T1 mapping for diagnosis and risk-stratification in cardiac sarcoidosis.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical utility and optimal analytical approach for native T1 mapping in cardiac sarcoidosis (CS) remain unclear. This study investigated the clinical value of segmental native T1 assessment in patients with CS. Methods: We recruited 55 participants, including 41 patients undergoing diagnostic evaluation of CS and 14 healthy controls. Of the 41 patients, 29 were diagnosed with CS and 12 were classified as non-CS. Segmental cardiac magnetic resonance findings of the left ventricle were evaluated using a 1.5-T scanner. The primary endpoint was a composite of all-cause death, fatal ventricular arrhythmia, bradycardia, or hospitalization for cardiovascular events. Results: Maximum and global native T1 values were significantly higher in CS patients than in healthy controls and non-CS patients. Maximum and global T1 values demonstrated comparable predictive performance in differentiating CS from the other groups, with areas under the curve (AUCs) of 0.92 and 0.90, respectively. The AUC for predicting segments with late gadolinium enhancement (LGE) was highest for extracellular volume, followed by native T1 and T2 ( Conclusions: Maximum and global native T1 values were highly predictive for differentiating CS. The high segmental native T1 values in patients with CS may reflect the regional presence of LGE. Segmental native T1 assessment can aid in estimating long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.